correct impress rais pt
vertex report sales/earn provid busi updat
base robust result acceler pipelin rais pt
sales/earn number among highest
street pre-launch symdeko due dilig survey note indic
robust pent-up demand product forecast sales/earn upgrad
cycl februari expect cycl continu
modest pace patient recruit triplet therapi phase
commenc quickli feel nda file fda
eu shortli thereaft like stay bullish note correct includ updat
manag bullish file
triplet like later patient recruit complet
homozyg hetmin phase
move faster expect import signific portion
on-going re-rat occur approv uptak
variou measur look expens howev note
believ best sales/earn momentum profil large-cap
biotechnolog beyond see doubl
sale tripl non-gaap ep speed
triplet uptakesal could quadrupl earn sextupl room upsid
near term investor pay attent reimburs
landscap patient qualifi cf drug variou countri
reimburs pushback increas recent new york franc
ireland last year negoti fraught believ
strength triplet risk/benefit profil eventu convinc reimburs
recent note futur competit intens also decreas
recent stumbl glpg/abbv real question big
cf franchis quickli get
non-trivi question believ posit execut
deliv prioriti
note address linger investor concern opex
spend disciplin last qs early-stag pipelin interest
area b-thal pain scd etc also model nol keep
cash tax exceedingli low recent chang tax law due
global biotechnolog
compani discov develop
seriou diseas
analyst certif import disclosur see disclosur
orkambi achiev patient penetr homozyg
tez/iva success approv get
homozyg penetr
slower expect eu launch orkambi franc
price
triplet mid-stag clinic trial news flow
provid visibl pipelin beyond cf
rate vertex outperform price target
compani posit deliv strong sale earn
growth next five year potenti even
greater growth near- tezacaftor/ivacaftor mid-term triplet
therapi homozyg cf patient
product launch outperform opex reach steadi state
could begin upsid stori believ
orkambi reimburs approv addit ex-u
ivacaftor approv children month pdufa phase
data tez/iva age year ivacaftor age month
complet enrol four phase triplet regimen
submit nda triplet regimen
advanc next-gener corrector pipelin
vertex secur broad reimburs cf franchis ex-u
rapidli expect
tez/iva sale ramp faster expect
triple-combin regimen tez/iva plu anoth corrector
approv market hetmin popul
disclos addit pipelin opportun
failur secur orkambi regulatori approv australia
reimburs europ canada australia near term
lower expect uptak orkambi/tez/iva
compet regimen other abbvie/galapago
approv earlier expect take signific market share
util composit valuat methodolog biotech compani util forward price-to-earnings multipl npv adj estim earn
sinc biotech sector high-growth/high-expect sector aim rank target compani base qualiti sale and/
earn growth versu peer group peer index nbi expect earn growth next three
five year well expect higher termin multipl due perceiv greater certainti qualiti
sales/earn growth appli discount rate vs peer group average
slow orkambi sale disappoint commerci launch penetr tezacaftor/ivacaftor pipelin failur and/or regulatori
non-approv kalydeco label extens
statement oper varianceproduct revenu product develop gener administr asset impair cost expens loss oper incom expens incom expens loss provis benefit incom tax benefit incom incom loss incom loss attribut vertex outstand
statement revenu royalti collabor total product royalti research develop sale gener administr restructur expenses- intang asset impair charges- total cost expens incom loss oper interest incom net- interest expens incom expens incom loss provis benefit incom tax provis benefit incom net incom loss net incom loss attribut vertex dilut share outstand sale oper
price compani mention report
